Characteristics of patients and specific data collected
| BMI (n=581) | |
| Weight, mean kg (SD) | 79.4 (16.6) |
| BMI, mean (SD) | 26.8 (4.7) |
| BMI<18.5, n (%) BMI 18.5–24.9, n (%) BMI 25–29.9, n (%) BMI 30–34.9, n (%) BMI 35–39.9, n (%) BMI>40, n (%) | 5 (1) 216 (37) 244 (42) 84 (15) 21 (4) 11 (2) |
| BMI<18.5–29.9, n (%) BMI≥30, n (%) | 465 (80) 116 (20) |
| ASA classification (n=683) | |
| ASA class 1, n (%) ASA class 2, n (%) ASA class 3, n (%) ASA class 4, n (%) | 253 (37) 348 (51) 76 (11) 6 (<1) |
| Anti-coagulants (n=683) | |
| Anti-coagulants, n (%) Platelet inhibitors, n (%) Warfarin, n (%) NOAC, n (%) Anti-Xa (fragmin, LMWH), n (%) No anti-coagulant treatment, n (%) | 144 (21) 102 (15) 34 (5) 7 (1) 1 (<1) 539 (79) |
| Medication for cardiovascular disease (n=683) | |
| Cardiovascular disease, n (%) No cardiovascular disease, n (%) | 124 (18) 559 (82) |
| Medication for hypothyroidism (n=683) | |
| Levothyroxine, n (%) No levothyroxine treatment, n (%) | 41 (6) 642 (93) |
| Medication for hypertension (n=683) | |
| Anti-hypertensives, n (%) No anti-hypertensive treatment, n (%) | 286 (42) 397 (59) |
| Diabetes (n=683) | |
| Type I, n (%) | 4 (<1) |
| Type II, n (%) | 28 (4) |
| Metformin treatment, n (%) | 11 (2) |
| Insulin treatment, n (%) | 8 (1) |
| Other medications (n=200) | |
| Statins, n (%) | 39 (20) |
| Diuretics, n (%) | 30 (15) |
Anti-Xa, factor Xa inhibitors; ASA, American Society of Anesthesiologists physical status classified from 1 to 4; BMI, body mass index; LMWH, low-molecular-weight heparin; NOAC, non-vitamin K antagonist oral anticoagulants; SD, standard deviation.